This page shows the latest ViraTherapeutics news and features for those working in and with pharma, biotech and healthcare.
Boehringer Ingelheim made a big play in the category when it bought ViraTherapeutics for $236m last September, as did Merck with its $394m purchase of Viralytics, while Abbvie and Johnson &Johnson
Last year, Boehringer also acquired the oncolytic virus specialist ViraTherapeutics for 210m and licensed a checkpoint inhibitor from OSE Immunotherapeutics in a deal valued at up to 1bn.
Acquires ViraTherapeutics in a 210m takeover deal. Boehringer Ingelheim’s shopping spree in immuno-oncology has continued with a 210m takeover of ViraTherapeutics, an oncolytic virus specialist it has been working ... The privately-held German
by ViraTherapeutics in 2016.
Boehringer Ingelheim has boosted its position in immuno-oncology by licensing an oncolytic virus therapy developed by Austrian biotech ViraTherapeutics. ... The deal also gives Boehringer an option to acquire ViraTherapeutics outright once phase I
More from news
Approximately 1 fully matching, plus 4 partially matching documents found.
AstraZeneca. Anti-NKG2A antibody (monalizumab), IPH5201 (antibody targeting CD38) and Lumoxiti. #. for hairy cell leukaemia. Development &. commercialisation. collaboration. $307m. ViraTherapeutics/. Boehringer Ingelheim.
With a headline value of $235m Boehringer Ingelheim entered into a collaboration with ViraTherapeutics to develop an oncolytic virus therapy platform. ... Boehringer also secured the option to acquire ViraTherapeutics after development of VSV-GP. .
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...